Medgenics Set for U.S. Trial of Autologous EPO Biopump
By Nuala Moran
Wednesday, May 23, 2012
LONDON Medgenics Inc. got the go-ahead for the first U.S. trial of its autologous biopump technology, with the FDA approving a Phase IIb trial of Epodure, an implant of a patient's own skin that has been engineered to manufacture erythropoietin (EPO).
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.